An interventional study of High flow nasal cannula HFNC in SARS-CoV Infection and SARS (Severe Acute Respiratory Syndrome), sponsored by Lahore General Hospital. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-12-08.
Sponsored by Lahore General Hospital · Not applicable, Interventional, and Treatment
Many non-invasive ventilatory choices are available for COVID-19 patient who are having mild to moderate respiratory distress and their use will decrease the chance of ICU admission, intubation and mechanical ventilation in severe cases of COVID-19. However, all these respiratory supports and oxygen supply devices are aerosol generating and their selection should be precised enough to control nosocomial spread.
High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen. In acute respiratory failure HFNC is proven to be very effective and it also reduced the need of mechanical ventilation in severe patients. Apart from the supply of oxygen, HFNC generating positive airway pressure and decreasing the rebreathing from anatomical dead space.
Prone position is also a save therapy and has been proven to be effective for refractory hypoxia by increasing tidal volume, oxygenation and diaphragmatic functions in ARDS patients. Recent studies showed that prone positioning and HFNC might avoid the prerequisite of intubation in moderate to severe patients of ARDS and as a result it decreases the nosocomial infection in physicians who are doing these aerosol generating procedures.
This is observational single-center study, that will be done at Lahore General Hospital in which 95 beds are allocated for COVID-19 patients including ICUs and HDUs. Ethical approval will be obtained from research ethical committee of Lahore General hospital, Lahore. Informed consent will be obtained from all patients who will agree to publish their data in this research. We will protect patient's privacy and obey with the Helsinki Declaration.
7,638 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's planned enrollment of 30 is below the median of 100 across 4,098 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Lahore General Hospital is the lead sponsor of 27 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Review effect of HFNC as clinical trial among hospitalized patients with COVID-19 infection.
Device: High flow nasal cannula HFNC
High flow nasal cannula HFNC is a device that delivered the warmed and humid air on high flow rate through nose. It is used to treat severe respiratory distress in COVID-19 patients, a non-invasive ventilatory approach which is relative comfortable by using humidified and pre-heated air containing large concentration of oxygen.
Also known as: HFNC
Clinical response of HFNC
The number of patients treated with non-invasive ventilation devices. HFNC related events (hot air feeling, nasal lesions)
Time frame: 10 days
Duration of intervention
Length of HFNC therapy to COVID-19 patients
Time frame: 15 days
Duration of hospitalization
Number of days of hospital admission either in ICU or HDUs till date of discharge
Time frame: 15 days
Supplemental Oxygen Requirement from Baseline
Duration of increased supplemental oxygen requirement from baseline
Time frame: 15 days
Radiological outcome
Follow up radiological response HR-CT.
Time frame: 15 days
Plan to share: No
This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lahore General Hospital